Novanta agrees to acquire Riverpoint Medical for $1.2B cash

Novanta (NASDAQ:NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a developer and manufacturer of specialized minimally invasive surgical consumables, for an upfront cash consideration of $1.2 billion.

The deal includes an additional $250 million milestone payment scheduled for the first quarter of 2027, according to a corporate statement on Tuesday.

Novanta, a technology partner to global medical and industrial original equipment manufacturers, is purchasing the asset from Arlington Capital Partners, a private investment firm based in the Washington, D.C. area.

The acquisition marks a major strategic expansion for Novanta into the advanced surgical fibers and specialized devices market.

Riverpoint Medical focuses on private-label minimally invasive surgical consumables and instruments used across high-growth healthcare applications, including sports medicine, trauma care, and cardiovascular surgery.

Integrating Riverpoint’s portfolio aligns with Novanta’s ongoing strategy to shift its product mix toward more durable, recurring revenue streams.

The transaction is expected to close during the third quarter of 2026, subject to customary closing conditions and required regulatory approvals.